Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease

Journal of Neuroimmunology

Volumn 214, Issue 1-2, 2009, Pages 128-131

  Fernandes, Karla S S ^a   Brum, Doralina Guimaraes ^a   Sandrim, Valeria Cristina ^a   Guerreiro, Carlos Tostes ^a   Barreira, Amilton Antunes ^a   Tanus Santos, José Eduardo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

EDSS; Haplotypes; Matrix metalloproteinase 9; Multiple sclerosis; Pharmacogenetics; Polymorphism

Indexed keywords

ADENINE; CYTOSINE; GELATINASE B; THYMINE;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAZIL; CASE-CONTROL STUDIES; DISABILITY EVALUATION; DISABLED PERSONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX;

EID: 69949190038     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.07.004     Document Type: Article

References (35)

1. Avolio C., Ruggieri M., Giuliani F., Liuzzi G.M., Leante R., Riccio P., Livrea P., and Trojano M. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J. Neuroimmunol. 136 (2003) 46-53
2. Benesova Y., Vasku A., Stourac P., Hladikova M., Beranek M., Kadanka Z., Novotna H., and Bednarik J. Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis. J. Neuroimmunol. 205 (2008) 105-109
3. Boz C., Ozmenoglu M., Velioglu S., Kilinc K., Orem A., Alioglu Z., and Altunayoglu V. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin. Neurol. Neurosurg. 108 (2006) 124-128
4. Brum D.G., Barreira A.A., Louzada-Junior P., Mendes-Junior C.T., and Donadi E.A. Association of the HLA-DRB1*15 allele group and the DRB1*1501 and DRB1*1503 alleles with multiple sclerosis in White and Mulatto samples from Brazil. J. Neuroimmunol. 189 (2007) 118-124
5. Comabella M., Rio J., Espejo C., Ruiz de Villa M., Al-Zayat H., Nos C., Deisenhammer F., Baranzini S.E., Nonell L., Lopez C., Julia E., Oksenberg J.R., and Montalban X. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin. Immunol. 20 (2008) 20
6. Crawford D.C., and Nickerson D.A. Definition and clinical importance of haplotypes. Annu. Rev. Med. 56 (2005) 303-320
7. Demacq C., Vasconcellos V.B., Marcaccini A.M., Gerlach R.F., Silva Jr. W.A., and Tanus-Santos J.E. Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. Clin. Chem. Lab. Med. 46 (2008) 57-63
8. Fainardi E., Castellazzi M., Bellini T., Manfrinato M.C., Baldi E., Casetta I., Paolino E., Granieri E., and Dallocchio F. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult. Scler. 12 (2006) 294-301
9. Fiotti N., Zivadinov R., Altamura N., Nasuelli D., Bratina A., Tommasi M.A., Bosco A., Locatelli L., Grop A., Cazzato G., Guarnieri G., Giansante C., and Zorzon M. MMP-9 microsatellite polymorphism and multiple sclerosis. J. Neuroimmunol. 152 (2004) 147-153
10. Fiotti N., Altamura N., Fisicaro M., Carraro N., Uxa L., Grassi G., Torelli L., Gobbato R., Guarnieri G., Baxter B.T., and Giansante C. MMP-9 microsatellite polymorphism and susceptibility to carotid arteries atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1330-1336
11. Galboiz Y., Shapiro S., Lahat N., Rawashdeh H., and Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann. Neurol. 50 (2001) 443-451
12. Gijbels K., Masure S., Carton H., and Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41 (1992) 29-34
13. Hauser S.L. Multiple lessons for multiple sclerosis. N. Engl. J. Med. 23 (2008) 1838-1841
14. Jones G.T., Phillips V.L., Harris E.L., Rossaak J.I., and van Rij A.M. Functional matrix metalloproteinase-9 polymorphism (C-1562T) associated with abdominal aortic aneurysm. J. Vasc. Surg. 38 (2003) 1363-1367
15. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
16. Lamblin N., Bauters C., Hermant X., Lablanche J.M., Helbecque N., and Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J. Am. Coll. Cardiol. 40 (2002) 43-48
17. Lee Y.J., Woo M., Nam J.H., Baek J., Im C.H., Lee E.Y., Lee E.B., Park K.S., and Song Y.W. Matrix metalloproteinase-9 promoter polymorphisms in Korean patients with systemic lupus erythematosus. Hum. Immunol. 69 (2008) 374-379
18. Liuzzi G.M., Trojano M., Fanelli M., Avolio C., Fasano A., Livrea P., and Riccio P. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult. Scler. 8 (2002) 222-228
19. Maeda S., Haneda M., Guo B., Koya D., Hayashi K., Sugimoto T., Isshiki K., Yasuda H., Kashiwagi A., and Kikkawa R. Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. Kidney 4 (2001) 1428-1434
20. Minagar A., Alexander J.S., Schwendimann R.N., Kelley R.E., Gonzalez-Toledo E., Jimenez J.J., Mauro L., Jy W., and Smith S.J. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch. Neurol. 65 (2008) 199-204
21. Morgan A.R., Zhang B., Tapper W., Collins A., and Ye S. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J. Mol. Med. 81 (2003) 321-326
22. Nelissen I., Vandenbroeck K., Fiten P., Hillert J., Olsson T., Marrosu M.G., and Opdenakker G. Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. J. Neuroimmunol. 105 (2000) 58-63
23. Nelissen I., Dubois B., Goris A., Ronsse I., Carton H., and Opdenakker G. Gelatinase B, PECAM-1 and MCP-3 gene polymorphisms in Belgian multiple sclerosis. J. Neurol. Sci. 200 (2002) 43-48
24. Nelissen I., Martens E., Van den Steen P.E., Proost P., Ronsse I., and Opdenakker G. Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy. Brain 126 (2003) 1371-1381
25. Opdenakker G., Nelissen I., and Van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol. 12 (2003) 747-756
26. Parks W.C., Wilson C.L., and Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev., Immunol. 4 (2004) 617-629
27. Peters D.G., Kassam A., St Jean P.L., Yonas H., and Ferrell R.E. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 30 (1999) 2612-2616
28. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., and Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58 (2005) 840-846
29. Proost P., Van Damme J., and Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 192 (1993) 1175-1181
30. Sandrim V.C., Coelho E.B., Nobre F., Arado G.M., Lanchote V.L., and Tanus-Santos J.E. Susceptible and protective eNOS haplotypes in hypertensive black and white subjects. Atherosclerosis 186 (2006) 428-432
31. Sandrim V.C., de Syllos R.W., Lisboa H.R., Tres G.S., and Tanus-Santos J.E. Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus. Atherosclerosis 189 (2006) 241-246
32. Smallwood L., Allcock R., van Bockxmeer F., Warrington N., Palmer L.J., Iacopetta B., Golledge J., and Norman P.E. Polymorphisms of the matrix metalloproteinase 9 gene and abdominal aortic aneurysm. Br. J. Surg. 95 (2008) 1239-1244
33. Stephens M., Smith N.J., and Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68 (2001) 978-989
34. Zhang B., Ye S., Herrmann S.M., Eriksson P., de Maat M., Evans A., Arveiler D., Luc G., Cambien F., Hamsten A., Watkins H., and Henney A.M. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99 (1999) 1788-1794
35. Zivkovic M., Djuric T., Dincic E., Raicevic R., A2 lavantic D., and Stankovic A. Matrix metalloproteinase-9 - 1562 C/T gene polymorphism in Serbian patients with multiple sclerosis. J. Neuroimmunol. 189 (2007) 147-150